Maximilian J Hochmair1, Alessandro Morabito2, Desiree Hao3, Cheng-Ta Yang4, Ross A Soo5, James C-H Yang6, Rasim Gucalp7, Balazs Halmos7, Angela Märten8, Tanja Cufer9. 1. Department of Respiratory & Critical Care Medicine, Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Krankenhaus Nord, 3500 Vienna, Austria. 2. Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione G. Pascale"-IRCCS, 80131 Napoli, Italy. 3. Tom Baker Cancer Center, Cummings School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada. 4. Department of Thoracic Medicine, Chang Gung Memorial Hospital, 333 Taoyuan, Taiwan. 5. Department of Haematology-Oncology, National University Hospital, Singapore. 6. Department of Oncology, National Taiwan University Hospital & National Taiwan University Cancer Center, Taipei, Taiwan. 7. Department of Oncology, Montefiore/Albert Einstein Cancer Center, Bronx, NY 10461, USA. 8. Boehringer Ingelheim International GmbH, 55216 Ingelheim am Rhein, Germany. 9. University Clinic Golnik, University of Ljubljana, 4204 Ljubljana, Slovenia.
Abstract
Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. Clinical Trial Registration: NCT03370770 (ClinicalTrials.gov).
Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. Clinical Trial Registration: NCT03370770 (ClinicalTrials.gov).
Authors: Wang Chun Kwok; James Chung Man Ho; Terence Chi Chun Tam; Mary Sau Man Ip; David Chi Leung Lam Journal: Thorac Cancer Date: 2022-06-06 Impact factor: 3.223
Authors: Sung Yong Lee; Chang-Min Choi; Yoon Soo Chang; Kye Young Lee; Seung Joon Kim; Sei Hoon Yang; Jeong Seon Ryu; Jeong Eun Lee; Shin Yup Lee; Ji Young Park; Young-Chul Kim; In-Jae Oh; Chi Young Jung; Sang Hoon Lee; Seong Hoon Yoon; Juwhan Choi; Tae Won Jang Journal: Transl Lung Cancer Res Date: 2021-12